Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 slips as ex-dividend trades weigh, Rolls-Royce soars

Thu, 23rd Feb 2023 17:10

Rolls-Royce jumps on upbeat forecast

*

Major banks and healthcare stocks trade ex-div

*

FTSE 100 down 0.3%, FTSE 250 adds 0.6%

Feb 23 (Reuters) - The FTSE 100 ended lower on Thursday, as several banking and healthcare heavyweights traded ex-dividend, although shares of Rolls-Royce zoomed more than 20% after the aeroplane engine maker reported upbeat results.

The blue-chip index was down 0.3%, declining for a third straight session.

Shares of banks including Barclays and Standard Chartered and healthcare majors AstraZeneca and GSK slipped as they traded without entitlement for dividend payout.

Limiting losses on the FTSE 100 however Rolls-Royce surged 23.7% to post its biggest percentage gain in more than two years after the company's CEO forecast more profit growth in 2023.

"There was a lot of concern coming into this year generally about margins, results and (if) companies would be able to maintain their margins," said Caroline Simmons, UK chief investment officer at UBS Global Wealth Management.

"But what we've been seeing is so far the results have been broadly okay."

The FTSE 250 midcap index rose 0.6%, with John Wood Group Plc jumping 29.0% to the top of the index after the oilfield services and engineering firm said it received and rejected takeover proposals from Apollo Global Management.

Meanwhile, Bank of England interest rate-setter Catherine Mann said that it was

too soon to say

the risks posed by the surge in inflation last year had eased and that the central bank should continue to raise borrowing costs.

"Right now, the main driver for equities is just this reassessment of whether we have in fact priced peak rates, even if it means the recession is not coming," said Michael Metcalfe, head of macro strategy at State Street Global Markets.

Strong economic data in January has shaken investor confidence, he added.

Among other single stocks, Mondi fell 4.8% after the paper packaging company gave a cautious outlook.

Drax Group lost 3.7% as analysts said falling forward sales could hit the power generation firm's core earnings in 2024. The company posted annual profit that beat analysts' expectation. (Reporting by Shashwat Chauhan and Shristi Achar A in Bengaluru; editing by Uttaresh.V, Eileen Soreng and Andrew Heavens)

More News
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more
1 Sep 2023 07:12

Japan considering GSK's Nucala drug for sinusitis treatment

(Sharecast News) - Japanese regulators are reviewing a new drug application for GSK's Nucala treatment to be used for the treatment of form of adult sinusitis, the biopharma giant announced on Friday.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more
23 Aug 2023 08:17

GSK gets positive results from shingles trial of Shingrix in China

(Alliance News) - GSK PLC on Wednesday celebrated positive results from the first-ever efficacy trial of its preventative shingles treatment, Shingrix, in China.

Read more
23 Aug 2023 07:04

GSK reports positive results from shingles vaccine trials in China

(Sharecast News) - GSK reported significant positive findings from its first efficacy trial of the 'Shingrix' shingles vaccine in China on Wednesday.

Read more
22 Aug 2023 13:09

UK's Wood Group raises profit forecast on contract wins; shares rise

CFO David Kemp to retire

*

Read more
21 Aug 2023 22:37

US FDA approves Pfizer's maternal RSV vaccine to protect infants

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.